Background. The use of natural health products in prostate cancer (PrCa) is high despite a lack of evidence with respect to safety and efficacy. Fish-derived omega-3 fatty acids possess anti-inflammatory effects and preclinical data suggest a protective effect on PrCa incidence and progression; however, human studies have yielded conflicting results. Methods. A search of OVID MEDLINE, Pre-MEDLINE, Embase, and the Allied and Complementary Medicine Database (AMED) was completed for human interventional or observational data assessing the safety and efficacy of fish-derived omega-3 fatty acids in the incidence and progression of PrCa. Results. Of 1776 citations screened, 54 publications reporting on 44 studies were included for review and analysis: 4 reports of 3 randomized controlled trials, 1 nonrandomized clinical trial, 20 reports of 14 cohort studies, 26 reports of 23 case-control studies, and 3 case-cohort studies. The interventional studies using fish oil supplements in patients with PrCa showed no impact on prostate-specific antigen levels; however, 2 studies showed a decrease in inflammatory or other cancer markers. A small number of mild adverse events were reported and interactions with other interventions were not assessed. Cohort and case-control studies assessing the relationship between dietary fish intake and the risk of PrCa were equivocal. Cohort studies assessing the risk of PrCa mortality suggested an association between higher intake of fish and decreased risk of prostate cancer-related death. Conclusions. Current evidence is insufficient to suggest a relationship between fish-derived omega-3 fatty acid and risk of PrCa. An association between higher omega-3 intake and decreased PrCa mortality may be present but more research is needed. More intervention trials or observational studies with precisely measured exposure are needed to assess the impact of fish oil supplements and dietary fish-derived omega-3 fatty acid intake on safety, PrCa incidence, treatment, and progression.
Introduction
Prostate cancer (PrCa) accounts for almost one quarter of cancers diagnosed among men. In Canada, there are approximately 24 000 new cancer cases (24% of all new male cancer cases) expected in 2015. 1 While 5-year survival rates have dramatically improved, PrCa is still the third leading cause of cancer death among men, with nearly 4000 deaths (10.1% of all male cancer deaths) expected in 2015 in Canada. 1 However, PrCa incidence and mortality varies 60-fold globally, with a dramatic increase observed in immigrants moving from lowto high-risk countries, suggesting that dietary and lifestyle factors play a role in its etiology and pathogenesis. 2 With
Canadian men having approximately a 1 in 8 (12.8%) lifetime probability of being diagnosed with prostate cancer, there is strong interest in dietary and natural health product (NHP) interventions, which may be effective in either the prevention or treatment of PrCa.
There is widespread evidence that many patients with PrCa take NHPs, frequently without any clinical supervision. Surveys conducted in the United States, Britain, Australia, and Canada suggest that complementary and alternative medicine (CAM) is widely used among prostate cancer patients; with estimates of CAM prevalence between 25 to 90% [3] [4] [5] [6] [7] and rates of disclosure to the patient's physician or oncologist as low as 25%. 8 Fish-derived omega-3 fatty acids have emerged as a topic of interest in the prevention and treatment of PrCa. The omega-3 fatty acids found in fish include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These fatty acids exhibit anti-inflammatory properties through their impact on prostaglandin synthesis. 9 Populations with a high consumption of fish, such as those in Japan and Alaskan Inuit, have lower rates of PrCa than populations who consume the more typical Western diet, where intake of fish and the anti-inflammatory fish-derived omega-3 fatty acids is generally lower, 2 and intake of pro-inflammatory omega-6 fatty acids is generally much higher. 10 Additionally, a wide range of mechanisms by which omega-3 fatty acids affect cancer development have been elucidated 11 and a large number of in vitro and animal studies show that EPA and DHA have inhibitory effects on PrCa growth and progression. [12] [13] [14] [15] [16] [17] Briefly, some of the chief mechanisms of action behind the cancer modulating effects of fish oil include the following: suppression of raft-associated signal transduction, promotion of BAD-dependent apoptosis via the PI3K/AKT survival pathway (phosphatidylinositol 3-kinase and serine/threonine protein kinase AKT), reduction of oxidative stress-induced endothelial Ca 2+ influx via transient receptor potential channels (TSPs) and nuclear factor erythroid-2-related factor 2 (Nrf2) activation, and resolution of inflammation through the action of E-resolvins (RvE1 and RvE2), D-resolvins (RvD1 and RvD2), and protectin (PD1) on cyclooxygenase (COX) and lipoxygenase (LOX) pathways. 18 The clinical potential of omega-3 fatty acids in the context of PrCa prevention and treatment remains controversial, and the results of numerous randomized controlled trials (RCTs), case-control studies, epidemiological reports, and systematic reviews assessing the role of fish-derived omega-3 fatty acids in the incidence and progression of PrCa have been largely inconsistent. The equivocal results are complicated by high variability in study methodology in terms of measurements of exposure (eg, food frequency questionnaires [FFQ] ; plasma, serum or prostate tissue fatty acid levels); PrCa outcomes (eg, incidence, mortality, or progression) and biomarkers (eg, prostate-specific antigen [PSA] or inflammatory markers such as cyclooxygenase-2) used to assess fish-derived omega-3 fatty acid status and clinical outcomes.
To our knowledge, there are no evidence-based guidelines currently available for patients or clinicians indicating whether fish-derived omega-3 fatty acids are safe or effective in the context of PrCa treatment, progression, and prevention. In the absence of guidelines, men often self-prescribe based on limited information found on the Internet or obtained from family and friends. 19 Patients and clinicians need to have access to reliable, credible, and evidence-based information about potential risks and benefits when making decisions about using NHPs in the context of PrCa. Because previous studies have reported mixed or conflicting result on the relationship between fish-derived omega-3 fatty acid and PrCa, thorough analysis of the entire body of literature is warranted. Therefore, we performed a systematic, evidence-based review of the available literature regarding fish-derived omega-3 fatty acids for the treatment and prevention of PrCa, with the purpose of developing comprehensive knowledge translation tools for oncology health professionals and, ultimately, patients with PrCa.
Methods
Methods of the analysis and inclusion criteria were specified in advance and documented in a registered protocol (PROSPERO 2014:CRD42014013014). 20 
Search Strategy
Electronic search strategies were developed by an experienced medical information specialist in consultation with the review team (Appendix A). Using the OVID platform, we searched OVID MEDLINE, Pre-MEDLINE, Embase, and the Allied and Complementary Medicine Database (AMED). We also searched the Cochrane Library on Wiley and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) on EBSCO and 2 Chinese-language databases (Wanfang and China National Knowledge Infrastructure databases). All database searches were performed on July 21, 2014 and updated June 21, 2015 . Searches included controlled vocabulary terms (eg, "Prostatic Neoplasms," "Fatty Acids, Omega-3," "Docosahexaenoic Acids") and key words (eg, prostate cancer, Omega 3, PUFAs). There were no language or date restrictions on any of the searches. ClinicalTrials.gov and the International Clinical Trials Registry Platform (ICTRP) were searched for current and completed clinical trials.
Inclusion Criteria
Eligible studies assessed male patients of any age for primary or secondary prevention or progression of PrCa. The studies assessed, used, or measured dietary and/or supplemental intake of fish-derived omega-3 fatty acids with or without other supplements or measured the omega-3 content in biological samples obtained from participants. Studies assessing non-fish-derived omega-3 fatty acids such as alpha-linoleic acid or flaxseed oil were excluded. Studies using placebos, comparator groups consisting of natural or pharmacological agents, or no control were eligible. Eligible study designs included RCTs, non-randomized controlled trials (non-RCTs), and observational studies (case-control, cohort) but not preclinical or cross-sectional studies.
Record Screening and Selection
All citations identified by the systematic search were downloaded into a reference database. Two investigators independently reviewed all identified titles and abstracts for eligibility. Disagreement regarding inclusion of records was determined by consensus and third party arbitration by another member of the research team, when appropriate. Duplicate reports of studies were included.
Data Extraction
Data were extracted independently by 2 investigators using data abstraction sheets that had been developed and piloted among the investigative team. Outcome measures extracted included relative risk (RR), hazard ratio (HR), and odds ratio (OR). Outcome measures that were adjusted for known PrCa risk factors such as age, ethnicity, family history, smoking status, and body mass index (BMI) were extracted when available. When not reported, unadjusted outcomes were extracted. Study authors were contacted to clarify results reported in 2 publications 21, 22 ; however, no new information was obtained.
Outcomes
The primary outcome of this review is primary prevention of PrCa. Secondary outcomes include PSA level, PSA doubling time, Gleason score, recurrence, tumor response rates, survival, immune function (clinical or surrogate parameters), quality of life (QOL), other cancer symptoms or chemotherapy-related side effects, adverse events/toxicities, the Eastern Cooperative Oncology Group (ECOG) and/or Karnofsky performance scores, Edmonton Symptom Assessment Scale (ESAS), prognostic scores (Glasgow PS), or other cancer markers or relevant surrogates. Additionally, we assessed for interactions, defined as a pharmacological or clinical responses to the administration or co-exposure of a treatment and another substance that modifies either the effectiveness or safety of the treatment.
23,24

Exposure
Data on the dose of fish-derived omega-3 fatty acid intake were extracted from the studies. When these data were not reported as mg of EPA + DHA per day, a conversion was performed to create a standardized dose by weight. To facilitate conversion when intake was reported in servings of fish, a standard of 0.798 g EPA + DHA per servings of fish was used. This was calculated by finding the average EPA + DHA content among the different fish and seafood types listed in the Dietitians of Canada online reference. 25 When intake of fatty acids was reported as a percentage of daily caloric intake, a standard of 2350 calories per day was utilized based on the Health Canada Food Guide recommendations for adult men with low activity level. The percentage was multiplied by 2350 calories and divided by 9 cal/g to approximate the grams of fish oil taken in per day.
Risk of Bias Assessment
The quality of clinical trials was assessed using the Cochrane Risk of Bias tool. 26 The quality of cohort and case-control studies was assessed using the Newcastle-Ottawa Scale. 27 All studies were assessed for their source of funding (industry vs nonindustry). Assessment was completed independently by 2 investigators and disagreement was resolved by consensus or third party arbitration, when appropriate. For nonrandomized trials, we assessed quality according to reporting of blinding of patients and assessors, a priori sample size estimation and low loss to follow-up (<20%).
Data Analysis
Analysis was completed separately for each type of study design. A random-effects model was used to pool results from the studies, including the following measures of effect and 95% confidence intervals (CIs): RR, HR, and OR. When available, adjusted measures of effect were used. Forest plots were created to display the results for different types of studies that were pooled. When available, the effect of total fish-derived omega-3 fatty acids on total incidence of cancer was utilized. When these statistics were not available, other statistics were reported, such as the effect of EPA only and DHA only on PrCa risk or the effects of omega-3 fatty acids on advanced and nonadvanced PrCa. Additional forest plots were created to display the effects of fishderived omega-3 fatty acid son PrCa mortality, to compare analyses of EPA alone to DHA alone and to compare studies utilizing different methods of assessing fish-derived omega-3 fatty acid exposure.
Planned sensitivity analyses included an assessment of the effect of methodological quality of included trials, withdrawals/losses to follow-up, and funding source, when feasible. Homogeneity was assessed using the I-squared statistic and the Zalen test. If some degree of homogeneity existed (I 2 < 75%), a meta-regression analysis (using STATA) was conducted to determine the extent to which factors contributed to heterogeneity. Variable coefficients are displayed in the beta-coefficient with 95% CIs and appropriate ORs with P values. A funnel plot test, using Eggers test for publication bias, was used to assess the likelihood of publication bias. Both quantitative (meta-analysis) and qualitative narrative synthesis of studies (based on study design) were planned.
Results
Of 1776 records screened, 54 publications, reporting on 44 studies, were included for review and analysis. Figure 1 shows a flowchart of the literature search and study selection. Search of the Chinese databases yielded 17 records, none of which met criteria for inclusion. Data extraction by 2 reviewers was found to have a high degree of agreement and consensus was reached on all articles. Meta-analysis was not completed due to the significant heterogeneity in the observational data and limited amount of interventional data. The results reported in the studies found were predominantly focused on cancer prevention. Eight publications reported on disease management and progression. [28] [29] [30] [31] [32] [33] [34] [35] Many of the secondary outcomes that were planned in this review were not assessed by any of the included studies.
Interventional Studies
Five publications [28] [29] [30] [31] [32] reported on the results of 4 clinical trials, including 1 non-RCT (Table 1) . Of the 4 trials, 1 was in patients with localized PrCA preprostatectomy, 29 1 in patients undergoing active surveillance, 31 1 in postprostatectomy patients, 28 and 1 in patients with untreated localized or regional PrCA. 32 Interventions included a low-fat diet plus fish oil supplementation (2400-5500 mg per day of fish oil providing 1600 to 2400 mg of EPA + DHA). PSA levels remained unchanged in all four trials (Table 1) . Many reported a lack of significant effect on inflammatory markers; however, there were significant reductions in malignant epithelial cell proliferation (Ki-67) in one of the trials (decrease of 32.2% P < .05) 29 and decreased cell-cycle progression score, pro-inflammatory fatty acids 15-S-hydroxyeicosatetraenoic acid and leukotriene B4 in another study 30 ( Table 1 ). The intervention studies analyzed were of short duration. Three of the 4 trials were three months or shorter in duration 29, 31, 32 and the remaining study was 2 years. 28 
Observational Evidence
Prospective Cohort Studies of Primary Prevention. Seventeen publications reported on 11 cohort studies investigating primary prevention of PrCA (Table 2 ). These studies assessed dietary fish-derived omega-3 fatty acids and supplementary fish oil intake (13 assessed diet alone, 1 assessed supplement intake alone, and 3 assessed both diet and supplement intake) and assessed incidence and mortality of PrCa over an average of 12.2 years (range 4-23.5 years). One additional study discussed in the nested case-control section of this review contained a prospective cohort component 36 that assessed the relationship between dietary intake and supplemental fish oil and the relationship with prostate cancer. In the studies assessing dietary intake, the highest quartile or quintile of intake was compared with the lowest, which included individuals who consumed very little or no dietary fish. Sixteen publications reported on the association of fish-derived omega-3 fatty acid intake with PrCa incidence. Of these, 3 studies 10,21,36 reported on advanced and nonadvanced prostate cancer separately resulting in a total of 19 analyses. The publications reported RR or HR and 12 publications reported outcomes that had been adjusted for other factors.
Of the 19 analyses assessing PrCa incidence, 12 did not show a statistically significant association. 10, 21, [37] [38] [39] [40] [41] [42] [43] [44] Five analyses showed a significant association between increased intake of fish-derived omega-3 fatty acids and decreased PrCa incidence. 36, [45] [46] [47] [48] In 2 of these studies, the authors concluded that statistical significance was achieved based on the P value despite nonsignificant 95%Cis. 45, 46 Two analyses reported a significant association between increased intake and increased PrCa risk. 36, 49 In a subanalysis, another study demonstrated a positive association (ie, increased PrCa) f/u, follow-up; Bl, baseline; ↓, decrease; ↑, increase; ↔ no effect; GS, Gleason score; FO fish oil; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; n-3, omega-3; NR, not reported; Supp, supplement.
Table 2. (continued)
with increased EPA intake but not with increased intake of DHA or EPA + DHA. 43 The results of the primary cohort studies are presented in a forest plot ( Figure 2) ; with the exception of 1 study where the data were not available. 44 Five prospective cohort analyses assessed the impact of fish oil supplements (or the combination of diet and fish oil supplements in 1 study); 4 demonstrated no statistically significant association with the risk of PrCa incidence. 43, 45, 46, 50 One demonstrated a relationship between daily supplemental fish oil intake in later life and a decrease in advanced PrCa incidence. 36 Among the 7 cohort study reports assessing the risk of death related to PrCa, 5 studies reported a significant association between higher intake of fish-derived fatty acids and decreased risk of death. 35, 41, 48, 51, 52 Of the 2 remaining studies, one showed a significant association between decreased risk of death and higher EPA intake and a nonsignificant association with higher total EPA + DHA. 10 The remaining study showed an association between decreased risk of death and higher total EPA + DHA intake that approached significance. 46 Prospective Cohort Studies of Secondary Prevention. Three publications reported on cohort studies assessing progression or risk of death among patients with PrCa (Table 3) . 31, 34, 35 In these 3 studies, patients underwent conventional individualized treatment for their PrCa. One study measured the time to PrCa-related death 35 while one defined progression as either PrCa death, bone metastases from PrCa, biochemical recurrence, or initiation of secondary treatment. 34 The third study asked the patient's treating physician to whether or not the patient's prostate cancer had recurred or progressed since the initial treatment 33 and when not available defined progression as 2 or more successive rises in PSA, initiation of second therapy or positive scans for metastasis. Two studies utilized an FFQ to assess dietary fish intake after diagnosis of PrCa and analyzed risk of disease progression; no impact from high fish intake was found 33, 34 . The third study assessed risk of PrCa death and found an association between lower risk and higher fish-derived omega-3 fatty acid intake in the year prior to diagnosis. 35 The results of the primary and secondary cohort studies assessing risk of death are presented together in a forest plot (Figure 3) .
Dose of Fish-Derived Omega-3 Fatty Acids.
Among the cohort studies, the amount of fish-derived omega-3 fatty acid intake in the highest quartile of dietary intake varied widely, Figure 2 . Risk of prostate cancer (PrCa) incidence with fish-derived omega-3 fatty acid intake: Prospective cohort studies. When the effect of fish-derived omega-3 fatty acid intake on total PrCa risk was not available, subanalyses reporting on different stages of cancer (eg, advanced cancer and nonadvanced cancer) are reported. *Study authors concluded that the results achieved statistical significance based on P value and confidence interval. ranging from approximately 200 to 1300 mg/d of EPA + DHA (Table 2) . No relationship between the dose of the exposure and study outcome was apparent. Individual studies reporting findings of increased risk of PrCA incidence, decreased risk of PrCA incidence, and no effect on risk of PrCA incidence had the following average intake of fishderived omega-3 fatty acids in the highest quartile: 577, 373, and 666 mg, respectively. Three case-cohort studies assessed the impact of fish intake on PrCa incidence (Table 4) . Two studies showed no association between fish intake and PrCa. 53, 54 One study showed no association between EPA intake and PrCa and a relationship between higher dietary intake of DHA and higher incidence of PrCa. 55 Sixteen publications reported on 15 case-control studies and 10 publications reported on 8 nested case-control studies. These results are presented in Tables 5 and 6 and displayed in Figures 4 and 5 . There was considerable heterogeneity in the results of the different studies as well as the methodology, analyses and reporting in individual studies. The studies varied in their method of assessing exposure, the time of exposure, the type of fish eaten and the marine fatty acids measured (EPA, DHA, EPA + DHA). Of the case-cohort, case-control, and nested case-control studies, 10 utilized whole blood, plasma, serum or RBC fatty acid analysis to assess fish-derived omega-3 fatty acid exposure, whereas 21 assessed intake through participant recall using a FFQ.
Among those that assessed fish-derived omega-3 fatty acid intake through recall with significant findings, 8 analyses showed an association between higher intake and lower risk of PrCa incidence 56-61 while 4 analyses showed an association with higher risk of incidence. 36, [61] [62] [63] Among the studies that assessed blood levels, 3 analyses reported an association between higher intake and lower risk 22, 41 and 5 reported an association with higher risk of incidence. 40, 50, 55, 64, 65 Among the studies reporting an association between higher fish intake on recall and higher risk, the type of fish intake assessed was related to the outcome. One study showed an association with increased risk with higher intake of cod, saithe, shellfish, and "fish fingers" but an association with decreased risk with higher intake of salmon-type fish while adjusting for intake of the other fish types. 61 It also showed that when overall intake of EPA + DHA was assessed, the effect was protective. Another study showed an association with increased risk with higher white fish intake (unadjusted for intake of other fish) and no effect from higher intake of tuna, dark fish, or deep fried fish. 63 Another study that found an association with increased risk reported mixed results including an increased risk of advanced PrCa with higher intake of salted or smoked fish in early life, a lower risk of localized PrCa with intake later in life and no effect on other stages of PrCa and other intake time points. 36 No case-cohort, case-control, or nested case-control studies reported on the risk of death.
One case-control study assessed supplemental fish oil intake in addition to dietary fish intake; however, the intake amounts were combined in analysis to reflect overall fishderived omega-3 fatty acid intake. 66 One nested casecontrol study assessed supplemental fish oil intake and found that daily use in early or midlife was not associated with and PrCa risk. 36 When the observational results were organized by the type of fish-derived fatty acid analyzed (EPA and DHA), no association was observed (Figures 6 and 7) .
Adverse Events and Interactions. In the RCTs and non-RCT, adverse events ranged from none to mild. In 1 study, 2 of 32 subjects experienced nausea and withdrew. 28 One study reported increased flatulence (5 subjects compared with 1 in the placebo group), self-limiting diarrhea (2 participants compared with 1 in the placebo group), and eructation (1 participant). 29 Two studies stated that no adverse events were reported. 31, 32 No studies reported a statistically significant difference in adverse reaction rates between fish oil and control/placebo arm.
Among the studies that used fish oil supplement interventions in patients with PrCa, no interactions with conventional care were reported; however, the studies excluded many participants receiving conventional cancer therapies. Of the 3 RCTs and 1 non-RCT, 3 excluded men receiving antihormonal therapies, 2 excluded men receiving 5-alphareductase inhibitors, and 3 excluded men taking antiinflammatory medication. None of the studies included men receiving chemotherapy or radiation; 2 studies included men who were untreated, 31,32 1 included men postprostatectomy, 28 and 1 preprostatectomy. 29 No clinical studies specifically reported an active assessment of interactions with other therapies, surgical procedures, or medications.
Risk of Bias.
Among the RCTs, all studies had a high risk of bias when evaluated with the Cochrane Risk of Bias Assessment; the results are displayed in Figure 8 . Risk was identified in most studies due to incomplete outcome data and in Figure 4 . Risk of prostate cancer (PrCa) incidence with fish-derived omega-3 fatty acid intake: Case-cohort, case-control, and nested case-control studies using blood assessment of fatty acids. When the effect of total fish-derived omega-3 fatty acid intake on PrCa risk was not available, sub-analyses reporting on individual fatty acids or different stages of cancer are reported. Figure 5 . Risk of prostate cancer (PrCa) incidence with fish-derived omega-3 fatty acid intake: Case-cohort, case-control, and nested case-control studies using Food Frequency Questionnaire (FFQ) assessment of fatty acid exposure. When the effect of total fishderived omega-3 fatty acid intake on PrCa risk was not available, subanalyses reporting on individual fatty acids, different stages of cancer, and different time points of fish exposure are reported. Figure 6 . Risk of prostate cancer (PrCa) incidence with eicosapentaenoic acid (EPA) intake: Observational data. When the effect of total fish-derived omega-3 fatty acid intake on PrCa risk was not available, subanalyses reporting on individual fatty acids or different stages of cancer are reported. some studies due to lack of blinding for participants and in outcome assessment. Allocation concealment was unclear in all studies. Among the 3 RCTs, 1 was industry funded, 28 1 was non-industry funded, 29 and 1 was funded by a combination. 31 The 1 nonrandomized clinical trial did not use blinding, had no loss to follow-up; and a priori sample size estimation and funding source were unclear. 32 Among the observational studies, the cohort studies, case-control studies and case-cohort studies had an average score of 7.06, 7.27, and 8.33 out of 9, respectively, on the Newcastle-Ottawa Quality Assessment Scale. Two cohort studies were not assessed because full text publication in English was not available. 42, 44 The results are displayed in Figures 9, 10 , and 11. The most notable deficiency in both the cohort and case-control studies was for the ascertainment of fish-derived omega-3 fatty acid exposure as most studies relied on written, self-report of dietary information rather than a structured interview. Additionally, many of the case-control studies failed to report the difference in nonresponse rate between cases and controls. Among the observational studies, 40 were funded by nonindustry sources, 2 by a combination of industry and nonindustry sources, 34, 36 and 8 were unclear in their reporting of funding. 43, 47, [56] [57] [58] [67] [68] [69] 
Discussion
Summary of Findings
The interventional studies of fish-derived omega-3 in patients with PrCa showed no impact on PSA levels; however, some studies showed a decrease in inflammatory markers. A small number of mild adverse events were reported and interactions with other interventions were not assessed. Cohort, case-cohort and case-control studies assessing the risk of PrCa incidence were equivocal. Cohort studies assessing the risk of PrCa mortality suggested an association between higher intake and decreased risk. The results of this review are consistent with other systematic reviews conducted, 70, 71 which also assessed prevention and secondary PrCa outcomes using diet and supplement exposure and found no association.
Study Weaknesses: Method of Exposure Ascertainment in Observational Studies
While all of the cohort studies assessed patient-reported fish-derived omega-3 fatty acid intake to ascertain exposure, case-control and nested case-control studies utilized either patient questionnaires or blood levels to assess fish-derived omega-3 fatty acid exposure; however, both have limitations. The method of assessing fish-derived omega-3 fatty acid exposure may be of importance as more of the studies utilizing blood levels reported an association with increased risk of PrCa while more of the studies assessing self-reported intake reported an association with deceased risk of PrCa. A recent study compared the different methods of fish intake assessment. 72 They followed a group of men with low-risk PrCa undergoing active surveillance to first repeat biopsy and assessed relationships between the risk of progression and the different methods of fatty acid assessment-dietary recall, RBC fatty acids, and prostate tissue fatty acids. While dietary intake and RBC fatty acids were not correlated with risk of progression, men with the highest tertile of prostate EPA had a significantly lower risk of progression (OR = 0.08, 95% CI 0.01-0.72, P = .02).
Blood assessment is limited by the challenge of differentiating endogenously produced fats from those consumed and the impact of individually varying rates of metabolism and deposition in tissues as a result of genetic, dietary and lifestyle differences. 73 Additionally an individual fatty acid is reported as a percentage of total fatty acids, not as an absolute amount; as a result, larger intake of one fatty acid could affect the relative proportion of others. Lastly, disease can affect fatty acid levels; for example, tumors selectively take up high amounts of polyunsaturated fatty acids. 73 Among the studies included in this review that used blood samples, 9 of 12 assessed plasma or serum fatty acids, 2 assessed RBC fatty acids and 1 assessed whole blood. Plasma fatty acids are known to reflect short-term or recent fat intake while RBCs reflect the previous 3 weeks' to 3 months' intake due to their longer life span. 74 Considering the length of time required for the pathogenesis of cancerous lesions, these fatty acid evaluations that reflect relatively recent intake may be of limited utility in assessing a role in causation, particularly if the participant has made changes to their diet over time.
Diet recall also presents challenges, including intentionally or unintentionally inaccurate recall and low reproducibility. Studies assessing the reproducibility of FFQs for polyunsaturated fatty acids have found a Spearman correlation coefficient from 0.38 to 0.59. 75 With cancer known to develop over a long period of time, some of the shorter times between observation of exposure and outcome of interest may neither be sufficient to allow for detection, progression, or substantive change, nor represent the time when carcinogenesis or early cancer development occurred. Conversely, when studies asked participants to recall dietary patterns from 10 years ago, there could be concern about the patients' ability to do so accurately.
Possible Mechanisms of Protective Effect
There have been a number of proposed mechanisms by which fish-derived omega-3 fatty acids may influence PrCa risk or progression, largely related to their effect on decreasing inflammation through inhibition of the cyclooxygenase enzymes 76 and affecting the immune system. Inflammation is suspected to trigger PrCa progression 77 and the use of nonsteroidal anti-inflammatory drugs (NSAIDS) results in a decreased risk of PrCa. 61 In vitro studies assessing the impact of fish oil on PrCa cells demonstrate increased cancer cell death, 12 enhanced cytotoxic effects of docetaxel, 13 prolongation of the androgen-dependent state, 14 and inhibition of cell adhesion, invasion and migration, which effect metastasis. 15, 16 A mouse study comparing diets based on fish, olive, corn, or animal fat showed slowed tumor growth and increased survival in the fish oil group. 17 Alternatively, another factor in the fish may be exerting an anticancer effect. Dietary fish is a source of vitamin D 78 and while results are varied, vitamin D is suspected to have a possible protective effect in prostate cancer. 79 None of the studies reviewed assessed vitamin D levels; however, one study acknowledged that the protective effect of fish oil supplementation may have been related to the vitamin D content found in fish liver oil, the most common form of fish oil supplementation used in the study population. 36 
Possible Mechanisms of Harmful Effect
Some of the studies reviewed found associations between higher fish-derived omega-3 fatty acid exposure and PrCa incidence risk. No biological mechanism has been proposed to explain these results. The studies suggesting harm were more likely to be retrospective studies than prospective studies and many showed a combination of harmful, protective or null effect, resulting in unclear conclusions. Although they were of short duration, the intervention trials did not produce results suggesting a risk in the form of side effects, or negative effects on clinical outcomes such as laboratory markers or mortality. One study suggested that the omega-3:omega-6 ratio might be of more importance than the absolute amount of marine omega-3 intake because of their competitive metabolism and antagonistic effects on inflammation. 61 The study conducted by Joshi et al 63 explored the relationship between different types of fish, different methods of preparation, different levels of "done-ness" (ie, preconsumption cooking and/or preparation) and the risk of PrCa. Fish that was panfried or cooked to "well done" was associated with increased risk while fish cooked "just until done," "well done at low temperatures," and "just done at high temperatures" was not. The authors concluded that mutagenic heterocyclic amines produced in cooking might be responsible for the association.
Other studies hypothesized that environmental toxins, such as polychlorinated biphenyls found in the fish that was ingested, 43 or involved in processing and packaging, 62 could be the biologically active constituent responsible for the association with cancer rather than the fatty acids EPA + DHA.
While not part of this systematic review, a brief search of preclinical data yielded only 1 study showing procancer effects of EPA at low concentrations in cancer cell lines. The remaining 50 in vitro/in vivo studies reported anticancer effects or mechanisms of omega-3 fatty acids (Appendix B). Unlike the observational studies that posed very large challenges in assessing exposure, the cell culture and animal studies involved doses of fish oil exposure that were was precisely known.
Alternatively, the relationship may be related to a behavioral factor rather than a biological one. PrCa risk is increased with increasing education, which may be associated with more health conscious behaviors such as consuming dietary fish or fish oil supplements. 80 
Systematic Review Strengths and Limitations
Strengths of our review include a comprehensive search including all interventional and observational studies conducted in humans. Our methodology, including duplication of screening and data extraction demonstrates reliability of the synthesis.
One significant limitation of this review relates to primary research available and specifically the lack of well designed, long duration studies examining the effects of fish oil interventions in patients with or without PrCa. Of the 4 interventional studies reported on, 3 studies were 3 months or shorter in duration, which may not be an adequate length of time to observe a response to treatment, progression, recurrence of PrCa or to monitor long-term adverse events. Because of the relatively small number of studies assessing the role of fish oil in patients with PrCa, the majority of the evidence included in this review assessed primary prevention of PrCa. While this information may be useful in understanding a potential anticancer or procancer effect of these constituents, it is a significant limitation in answering the original question of whether or not fish oil supplementation is indicated in patients with PrCa. Because the majority of the studies were observational, the results provide limited information on causality and may reflect correlations or other associations. Additionally, the methods used to assess exposure possessed limitations. Although we included a large number of studies, it was not possible to pool the data due to heterogeneity.
Conclusions
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